PepGen

PepGen is a clinical-stage biotechnology company developing oligonucleotide therapies for severe neuromuscular and neurological diseases. Its proprietary EDO platform is designed to improve cellular delivery of therapeutic oligonucleotides, with programs including candidates for myotonic dystrophy type 1 and Duchenne muscular dystrophy.

Relationship details are part of the Pro plan.